2024

CARs come to AID
Ayuk F, Fehse B
MOL THER. 2024;32(4):861-862.

Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire
Eden T, Schaffrath A, Wesolowski J, Stähler T, Tode N, Richter N, Schäfer W, Hambach J, Hermans-Borgmeyer I, Woens J, Le Gall C, Wendler S, Linke-Winnebeck C, Stobbe M, Budnicki I, Wanney A, Heitz Y, Schimmelpfennig L, Schweitzer L, Zimmer D, Stahl E, Seyfried F, Gebhardt A, Dieckow L, Riecken K, Fehse B, Bannas P, Magnus T, Verdoes M, Figdor C, Hartlepp K, Schleer H, Füner J, Tomas N, Haag F, Rissiek B, Mann A, Menzel S, Koch-Nolte F
NAT COMMUN. 2024;15(1):4728.

Targeting T cell plasticity in kidney and gut inflammation by pooled single-cell CRISPR screening
Enk L, Hellmig M, Riecken K, Kilian C, Datlinger P, Jauch-Speer S, Neben T, Sultana Z, Sivayoganathan V, Borchers A, Paust H, Zhao Y, Asada N, Liu S, Agalioti T, Pelczar P, Wiech T, Bock C, Huber T, Huber S, Bonn S, Gagliani N, Fehse B, Panzer U, Krebs C
SCI IMMUNOL. 2024;9(96):eadd6774.

Chimeric autoantibody receptor cell therapy for the treatment of membranous nephropathy: The authors reply
Fehse B, Tomas N
KIDNEY INT. 2024;105(6):1320-1321.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, Richter J, Pfeffer L, Fehse B, Berger S, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese M, Heesen C, Kröger N
MED-CAMBRIDGE. 2024;5(6):550-558.e2.

CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture
Harfmann M, Schröder T, Głów D, Jung M, Uhde A, Kröger N, Horn S, Riecken K, Fehse B, Ayuk F
CANCERS. 2024;16(2):.

Wie sicher ist die Gentherapie? : Zweiter Todesfall nach Therapie der Duchenne-Muskeldystrophie
Horn S, Fehse B
INNERE MED. 2024;65(6):617-623.

Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N
LEUKEMIA. 2024;38(2):386-388.

The Histogenetic Origin of Malignant Cells Predicts Their Susceptibility towards Synthetic Lethality Utilizing the TK.007 System
Pallasch F, Freytag V, Kriegs M, Gatzemeier D, Mair T, Voss H, Riecken K, Dawood M, Fehse B, Efferth T, Schlüter H, Schumacher U
CANCERS. 2024;16(12):.

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard F, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N
AM J HEMATOL. 2024 [Epub ahead of print].

The potential of γδ CAR and TRuC T cells: An unearthed treasure
Schamel W, Zinchenko M, Nguyen T, Fehse B, Briquez P, Minguet S
EUR J IMMUNOL. 2024;54(11):e2451074.

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
Seifert L, Riecken K, Zahner G, Hambach J, Hagenstein J, Dubberke G, Huber T, Koch-Nolte F, Fehse B, Tomas N
KIDNEY INT. 2024;105(4):886-889.

IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction
Shiri A, Zhang T, Bedke T, Zazara D, Zhao L, Lücke J, Sabihi M, Fazio A, Zhang S, Tauriello D, Batlle E, Steglich B, Kempski J, Agalioti T, Nawrocki M, Xu Y, Riecken K, Liebold I, Brockmann L, Konczalla L, Bosurgi L, Mercanoglu B, Seeger P, Küsters N, Lykoudis P, Heumann A, Arck P, Fehse B, Busch P, Grotelüschen R, Mann O, Izbicki J, Hackert T, Flavell R, Gagliani N, Giannou A, Huber S
J HEPATOL. 2024;80(4):634-644.

HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells
Zecher B, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick M, Yuki Y, Martin M, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller L, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer M, Poch T, Sebode M, , Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer K, Schumacher U, Sauter G, Carrington M, Franke A, Bunders M, Schramm C, Altfeld M
GUT. 2024;73(2):325-337.

2023

Microglia colonize the developing brain by clonal expansion of highly proliferative progenitors, following allometric scaling
Barry-Carroll L, Greulich P, Marshall A, Riecken K, Fehse B, Askew K, Li K, Garaschuk O, Menassa D, Gomez-Nicola D
CELL REP. 2023;42(5):112425.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy
Berger S, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk F
HAEMATOLOGICA. 2023;108(2):444-456.

Einleitung: Gen- und Zelltherapie – „zwei Seiten zweier Medaillen“
Fehse B
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 11-21.

Genome-Editing – Gentherapie 2.0 oder nur eine Wunschvorstellung?
Fehse B, Grünewald J, Petri K
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 103-120.

Handlungsempfehlungen zur somatischen Gentherapie, Keimbahninterventionen und Zelltherapie
Fehse B, Walter J, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Müller-Terpitz R, Mundlos S, Jens R, Schicktanz S, Winkler E, Zenke M
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 1-10.

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N
HEMASPHERE. 2023;7(7):e921.

Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal
Grochowska K, Sperveslage M, Raman R, Failla A, Głów D, Schulze C, Laprell L, Fehse B, Kreutz M
CELL REP. 2023;42(8):112998.

Hämatopoetische Stammzelltransplantation: seit Jahrzehnten etablierte Zelltherapie
Kolb H, Fehse B
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: 161-181.

Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis
Luther M, Henes F, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2023;58(7):755-761.

Retrovirale Vektoren – Effiziente Gentaxis für unterschiedliche Gentherapien
Morgan M, Galla M, Fehse B, Schambach A
2023. Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft. Fehse B, Schickl H, Bartfeld S, Zenke M (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 25-49.

Correction: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Schwarze L, Głów D, Sonntag T, Uhde A, Fehse B
GENE THER. 2023;30(1-2):187.

Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation
Staffeldt L, Mattert G, Riecken K, Rövenstrunk G, Volkmar A, Heumann A, Moustafa M, Jücker M, Fehse B, Schumacher U, Lüth S, Kah J
CELLS-BASEL. 2023;13(1):.

Deep Characterization and Comparison of Different Retrovirus-like Particles Preloaded with CRISPR/Cas9 RNPs
Wichmann M, Maire C, Nuppenau N, Habiballa M, Uhde A, Kolbe K, Schröder T, Lamszus K, Fehse B, Głów D
INT J MOL SCI. 2023;24(14):11399.

2022

Immune Monitoring
Berger S, Fehse B, Rubio M
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 177-182.

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
Dadkhah A, Wicha S, Kröger N, Müller A, Pfaffendorf C, Riedner M, Badbaran A, Fehse B, Langebrake C
PHARMACEUTICS. 2022;14(6):.

The Reconstitution Dynamics of Cultivated Hematopoietic Stem Cells and Progenitors Is Independent of Age
Gotzhein F, Aranyossy T, Thielecke L, Sonntag T, Thaden V, Fehse B, Müller I, Glauche I, Cornils K
INT J MOL SCI. 2022;23(6):.

Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients
Hagemann K, Riecken K, Jung J, Hildebrandt H, Menzel S, Bunders M, Fehse B, Koch-Nolte F, Heinrich F, Peine S, Schulze Zur Wiesch J, Brehm T, Addo M, Lütgehetmann M, Altfeld M
EUR J IMMUNOL. 2022;52(8):1297-1307.

High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1
Kuzikov M, Woens J, Zaliani A, Hambach J, Eden T, Fehse B, Ellinger B, Riecken K
BIOMED PHARMACOTHER. 2022;151:.

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
Mannina D, Badbaran A, Wolschke C, Klyuchnikov E, Christopeit M, Fehse B, Kröger N
BONE MARROW TRANSPL. 2022;57(3):510-512.

Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts
Martin L, Kruchen A, Fehse B, Müller I
BIOMEDICINES. 2022;10(3):.

Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model
Moustafa M, Dähling K, Günther A, Riebandt L, Smit D, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki J, Fischer L, Nashan B, Li J, Jücker M
CANCERS. 2022;14(8):.

Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients
Schubert M, Berger C, Kunz A, Schmitt A, Badbaran A, Neuber B, Zeschke S, Wang L, Riecken K, Hückelhoven-Krauss A, Müller I, Müller-Tidow C, Dreger P, Kröger N, Ayuk F, Schmitt M, Fehse B
INT J ONCOL. 2022;60(5):.

2021

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Ayuk F, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, Zeschke S, Kröger N, Fehse B
BLOOD ADV. 2021;5(11):2523-2527.

Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues
Badbaran A, Mailer R, Dahlke C, Woens J, Fathi A, Mellinghoff S, Renné T, Addo M, Riecken K, Fehse B
MOL THER-METH CLIN D. 2021;23:418-423.

Neubewertung des Schutzes von In-vitro-Embryonen in Deutschland
Bartram C, Ellenberg J, Fehse B, Friedrich B, Kentenich H, Kumsta R, Niehrs C, Nöthen M, Schöne-Seifert B, Tanner K, Taupitz J, Thorn P, Vogel J, Wiesemann C, Winnacker E
2021.

Gene Therapy "Made in Germany": A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy
Büning H, Fehse B, Ivics Z, Kochanek S, Koehl U, Kupatt C, Mussolino C, Nettelbeck D, Schambach A, Uckert W, Wagner E, Cathomen T
HUM GENE THER. 2021;32(19-20):987-996.

In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
Carlet M, Völse K, Vergalli J, Becker M, Herold T, Arner A, Senft D, Jurinovic V, Liu W, Gao Y, Dill V, Fehse B, Baldus C, Bastian L, Lenk L, Schewe D, Bagnoli J, Vick B, Schmid J, Wilhelm A, Marschalek R, Jost P, Miething C, Riecken K, Schmidt-Supprian M, Binder V, Jeremias I
NAT COMMUN. 2021;12(1):5655.

Themenbereich somatische Gentherapie: aus dem Labor über klinische Studien zum kommerziellen Einsatz
Fehse B
2021. Fünfter Gentechnologiebericht. Fehse B, Hucho F, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Marx-Stölting L, Mundlos S, Osterheider A, Pichl A, Reich J, Schickl H, Schicktanz S, Taupitz J, Walter J, Winkler E, Zenke M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 156-183.

Anwendung des Genome Editing in der somatischen Gentherapie: Eine Einführung
Fehse B, Abramowski-Mock U
2021. Anwendung des Genome Editing in der somatischen Gentherapie. 1. Aufl. Wiesbaden: Springer, .

Einleitung: Gentechnologien in Deutschland im Fokus der IAG Gentechnologiebericht
Fehse B, Marx-Stölting , Schickl H, Khachatryan A
2021. Fünfter Gentechnologiebericht. Fehse B, Hucho F, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Marx-Stölting L, Mundlos S, Osterheider A, Pichl A, Reich J, Schickl H, Schicktanz S, Taupitz J, Walter J, Winkler E, Zenke M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 81-86.

Genome-Editing und Einzelzellanalyse: Neue Methoden und ihre Implikationen für Forschung, Anwendung und Gesellschaft
Fehse B, Walter J, Reich J, Marx-Stölting , Pichl A, Schickl H
2021. Fünfter Gentechnologiebericht. Fehse B, Hucho F, Bartfeld S, Clemens S, Erb T, Fangerau H, Hampel J, Korte M, Marx-Stölting L, Mundlos S, Osterheider A, Pichl A, Reich J, Schickl H, Schicktanz S, Taupitz J, Walter J, Winkler E, Zenke M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 219-250.

CRISPR-to-Kill (C2K)–Employing the Bacterial Immune System to Kill Cancer Cells
Glow D, Maire C, Schwarze L, Lamszus K, Fehse B
CANCERS. 2021;13(24):.

LATE-a novel sensitive cell-based assay for the study of CRISPR/Cas9-related long-term adverse treatment effects
Głów D, Meyer S, García Roldán I, Akingunsade L, Riecken K, Fehse B
MOL THER-METH CLIN D. 2021;22:249-262.

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Volker U, Hentschker C, Michalik S, Steil L, Reder A, Schönborn L, Beer M, Franzke K, Büttner A, Fehse B, Stavrou E, Rangaswamy C, Mailer R, Englert H, Frye M, Thiele T, Kochanek S, Krutzke L, Siegerist F, Endlich N, Warkentin T, Renné T
BLOOD. 2021;138(22):2256-2268.

Multiple genes surrounding Bcl-xL, a common retroviral insertion site, can influence hematopoiesis individually or in concert
Ha T, Stahlhut M, Rothe M, Paul G, Dziadek V, Morgan M, Brugman M, Fehse B, Kustikova O, Schambach A, Baum C
HUM GENE THER. 2021;32(9-10):458-472.

Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope
Mirow M, Schwarze L, Fehse B, Riecken K
VIRUSES-BASEL. 2021;13(8):.

Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Morgan M, Galla M, Grez M, Fehse B, Schambach A
GENE THER. 2021;28(9):494-512.

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke F, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain M, Subklewe M
BLOOD. 2021;138(24):2499-2513.

How to package and SEND mRNA: a novel "humanized" vector system based on endogenous retroviruses
Riecken K, Glow D, Fehse B
SIGNAL TRANSDUCT TAR. 2021;6(1):.

Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy
Schambach A, Morgan M, Fehse B
MOL THER. 2021;29(9):2631-2633.

mRNA Transfection of T-Lymphocytes by Electroporation
Schwarze L, Fehse B
Methods Mol Biol. 2021;2285:217-226.

Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Schwarze L, Głów D, Sonntag T, Uhde A, Fehse B
GENE THER. 2021;28(9):588-601.

Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients
Schwarze L, Sonntag T, Wild S, Schmitz S, Uhde A, Fehse B
GENE THER. 2021;28(9):572-587.

Vertically transferred maternal immune cells promote neonatal immunity against early life infections
Stelzer I, Urbschat C, Schepanski S, Thiele K, Triviai I, Wieczorek A, Alawi M, Ohnezeit D, Kottlau J, Huang J, Fischer N, Mittrücker H, Solano M, Fehse B, Diemert A, Stahl F, Arck P
NAT COMMUN. 2021;12(1):4706.

SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Wolters-Eisfeld G, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M
LEUKEMIA. 2021;35(4):1073-1086.

2020

Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A
Ayuk F, Fehse B, Janson D, Berger C, Riecken K, Kröger N
HAEMATOLOGICA. 2020;105(6):322-324.

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
Badbaran A, Berger C, Riecken K, Kruchen A, Geffken M, Müller I, Kröger N, Ayuk F, Fehse B
CANCERS. 2020;12(7):.

Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation
Christopeit M, Badbaran A, Alawi M, Flach J, Fehse B, Kröger N
BIOL BLOOD MARROW TR. 2020;26(7):e167-e170.

Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection against Injury-Induced Cell Death of Retinal Ganglion Cells in Mice
Dulz S, Bassal M, Flachsbarth K, Riecken K, Fehse B, Schlichting S, Bartsch S, Bartsch U
CELLS-BASEL. 2020;9(9):.

A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1
Ellinger B, Pohlmann D, Woens J, Jäkel F, Reinshagen J, Stocking C, Prassolov V, Fehse B, Riecken K
VIRUSES-BASEL. 2020;12(5):.

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
Fehse B, Badbaran A, Berger C, Sonntag T, Riecken K, Geffken M, Kröger N, Ayuk F
MOL THER-METH CLIN D. 2020;16:172-178.

Obituary Rolf Neth 1926-2020
Fehse B, Kröger N, Stocking C, Zander A
EXP HEMATOL. 2020;85:1-2.

Development of CAR-T cell therapies for multiple myeloma
Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk F, Fehse B, Kröger N
LEUKEMIA. 2020;34(9):2317-2332.

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Hambach J, Riecken K, Cichutek S, Schütze K, Albrecht B, Petry K, Röckendorf J, Baum N, Kröger N, Hansen T, Schuch G, Haag F, Adam G, Fehse B, Bannas P, Koch-Nolte F
CELLS-BASEL. 2020;9(2):.

Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
Hossain J, Marchini A, Fehse B, Bjerkvig R, Miletic H
NEURO-ONCOL ADV. 2020;2(1):vdaa013.

Glioma escape signature and clonal development under immune pressure
Maire C, Mohme M, Bockmayr M, Fita K, Riecken K, Börnigen D, Alawi M, Failla A, Kolbe K, Zapf S, Holz M, Neumann K, Dührsen L, Lange T, Fehse B, Westphal M, Lamszus K
J CLIN INVEST. 2020;130(10):5257-5271.

Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods
Mashel T, Tarakanchikova Y, Muslimov A, Zyuzin M, Timin A, Lepik K, Fehse B
BIOMATERIALS. 2020;258:120282.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf J, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P
THERANOSTICS. 2020;10(6):2645-2658.

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Atanackovic D, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2020;34(9):2542.

2019

Chancen und Risiken der CAR-T-Zell-Therapie
Ayuk F, Fehse B, Berger S, Riecken K, Kroger N
Hamb Ärztebl. 2019;73(10):30-32.

Cellular Therapy with Engineered T Cells, Efficacy and Side Effects
Bondanza A, Bonini C, Fehse B, Hudecek M
2019. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Springer Nature Switzerland AG, 449-456.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo
Giersch K, Bhadra O, Volz T, Allweiss L, Riecken K, Fehse B, Lohse A, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M
GUT. 2019;68(1):150-157.

Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma
Hossain J, Latif M, Ystaas L, Ninzima S, Riecken K, Muller A, Azuaje F, Joseph J, Talasila K, Ghimire J, Fehse B, Bjerkvig R, Miletic H
NEURO-ONCOLOGY. 2019;21(7):890-900.

Cancer Suicide Gene Therapy with TK.007
Hossain J, Riecken K, Miletic H, Fehse B
Methods Mol Biol. 2019;1895:11-26.

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours
Ricklefs F, Maire C, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland D, Flitsch J, Martens T, Schmidt N, Peine S, Breakefield X, Lawler S, Chiocca E, Fehse B, Giebel B, Görgens A, Westphal M, Lamszus K
J EXTRACELL VESICLES. 2019;8(1):1588555.

Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
Stürner K, Siembab I, Schön G, Stellmann J, Heidari N, Fehse B, Heesen C, Eiermann T, Martin R, Binder T
MULT SCLER J-EXP TRA. 2019;5(4):2055217319894615.

Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies
Tintelnot J, Baum N, Schultheiss C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schütze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M
MOL CANCER THER. 2019;18(4):823-833.

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M
FRONT ONCOL. 2019;9:1559.

2018

Clonal dynamics studied in cultured induced pluripotent stem cells reveal major growth imbalances within a few weeks
Brenière-Letuffe D, Domke-Shibamiya A, Hansen A, Eschenhagen T, Fehse B, Riecken K, Stenzig J
STEM CELL RES THER. 2018;9(1):165.

Consensus Statement of European Societies of Gene and Cell Therapy on the Reported Birth of Genome-Edited Babies in China
Büning H, Griesenbach U, Fehse B, Ylä-Herttuala S, Anagnou N, van Beusechem V, Raya A, Verhoeyen E
HUM GENE THER. 2018;29(12):1337–1338.

Genomeditierung durch CRISPR und Co
Fehse B
2018. Stammzellforschung. Zenke M, Marx-Stölting L, Schickl H (Hrsg.). 1. Aufl. Baden-Baden: Nomos, 97-114.

„Rote Gentechnologie“ – Nachhaltiges Comeback der Gentherapie?!
Fehse B
2018. Vierter Gentechnologiebericht . Hucho F, Diekämper J, Fangerau H, Fehse B, Hampel J, Köchy K, Könninger S, Marx-Stölting L, Müller-Röber B, Reich J, Schickl H, Taupitz J, Walter J, Zenke M, Korte M (Hrsg.). 1. Aufl. Baden-Baden: Nomos Verlagsgesellschaft, 210-214.

The Time Is Ripe for Somatic Genome Editing: NIH Program to Strengthen Translation
Fehse B, Abramowski-Mock U
MOL THER. 2018;26(3):671-674.

Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models
Frenzel T, Siekmann J, Grohmann C, Valentiner U, Schmitz R, Riecken K, Fehse B, Schumacher U, Lange T, Krüll A
INT J RADIAT ONCOL. 2018;100(4):1044-1056.

Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout
Knopp Y, Geis F, Heckl D, Horn S, Neumann T, Kuehle J, Meyer J, Fehse B, Baum C, Morgan M, Meyer J, Schambach A, Galla M
MOL THER-NUCL ACIDS. 2018;13:256-274.

Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma
Roh V, Abramowski P, Hiou-Feige A, Cornils K, Rivals J, Zougman A, Aranyossy T, Thielecke L, Truan Z, Mermod M, Monnier Y, Prassolov V, Glauche I, Nowrouzi A, Abdollahi A, Fehse B, Simon C, Tolstonog G
CELL REP. 2018;25(8):2208-2222.e7.

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia
Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M
BLOOD. 2018;131(15):1755-1758.

Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers
Timin A, Muslimov A, Lepik K, Epifanovskaya O, Shakirova A, Mock U, Riecken K, Okilova M, Sergeev V, Afanasyev B, Fehse B, Sukhorukov G
NANOMED-NANOTECHNOL. 2018;14(1):97-108.

High bone turnover in mice carrying a pathogenic Notch2-mutation causing Hajdu-Cheney syndrome
Vollersen N, Hermans-Borgmeyer I, Cornils K, Fehse B, Rolvien T, Triviai I, Jeschke A, Oheim R, Amling M, Schinke T, Yorgan T
J BONE MINER RES. 2018;33(1):70-83.

2017

Genetic barcodes facilitate competitive clonal analyses in vivo
Aranyossy T, Thielecke L, Glauche I, Fehse B, Cornils K
HUM GENE THER. 2017;28(10):926-937.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion
Cornils K, Thielecke L, Winkelmann D, Aranyossy T, Lesche M, Dahl A, Roeder I, Fehse B, Glauche I
MOL CANCER. 2017;16(1):120.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz M, Shahswar R, Ayuketang F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe H, Ganser A, Stocking C, Fehse B, Thol F, Heuser M
BIOL BLOOD MARROW TR. 2017;23(7):1095-1101.

Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity
Mohme M, Maire C, Riecken K, Zapf S, Aranyossy T, Westphal M, Lamszus K, Fehse B
MOL THER. 2017;25(3):621-633.

Mesenchymal stem cells engineering: microcapsules assisted gene transfection and magnetic cell separation.
Muslimov A, Timin A, Petrova A, Epifanovskaya O, Shakirova A, Lepik K, Gorshkov A, Il’inskaja E, Vasin A, Afanasyev B, Fehse B, Sukhorukov G
ACS BIOMATER SCI ENG. 2017;3(10):2314-2324.

ГЕННАЯ КЛЕТОЧНАЯ ТЕРАПИЯ ВИЧ И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КРОВЕТВОРНОЙ И ЛИМФАТИЧЕСКОЙ ТКАНИ НА ОСНОВЕ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ САЙТ-СПЕЦИФИЧЕСКОГО РЕДАКТИРОВАНИЯ ГЕНОМА
Popova M, Sergeev V, Lepik K, Shakirova A, Potter A, Barkhatov I, Fehse B, Afanasyev B
Zhurnal infektologii. 2017;9(1):31-39.

IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis
Riedel J, Becker M, Kopp K, Düster M, Brix S, Meyer-Schwesinger C, Kluth L, Gnirck A, Attar M, Krohn S, Fehse B, Stahl R, Panzer U, Turner J
J AM SOC NEPHROL. 2017;28(7):2068-2080.

SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model
Täger M, Horn S, Latuske E, Ehm P, Schaks M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J, Jücker M
GENE THER. 2017;24(11):749-753.

Limitations and challenges of genetic barcode quantification
Thielecke L, Aranyossy T, Dahl A, Tiwari R, Roeder I, Geiger H, Fehse B, Glauche I, Cornils K
SCI REP-UK. 2017;7:43249.

Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model
Thomaschewski M, Riecken K, Unrau L, Volz T, Cornils K, Ittrich H, Heim D, Wege H, Akgün E, Lütgehetmann M, Dieckhoff J, Köpke M, Dandri M, Benten D, Fehse B
ONCOTARGET. 2017;8(70):115582-115595.

Gene and Cell Therapy in Germany
von Kalle C, Fehse B, Büning H
HUM GENE THER. 2017;28(10):781.

Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuketang F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1526-1529.

2016

Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice
Abramowski P, Krasemann S, Ernst T, Lange C, Ittrich H, Schweizer M, Zander A, Martin R, Fehse B
STEM CELLS DEV. 2016;25(15):1134-48.

Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation
Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(6):872-3.

Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer
Bierwolf J, Volz T, Lütgehetmann M, Allweiss L, Riecken K, Warlich M, Fehse B, Kalff J, Dandri-Petersen M, Pollok J
TISSUE ENG PT A. 2016;22(9-10):742-53.

Investigation of the Mesenchymal Stem Cell Compartment by Means of a Lentiviral Barcode Library
Bigildeev A, Cornils K, Aranyossy T, Sats N, Petinati N, Shipounova I, Surin V, Pshenichnikova O, Riecken K, Fehse B, Drize N
BIOCHEMISTRY-MOSCOW+. 2016;81(4):373-81.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(10):1391-1393.

Microglia regulate hippocampal neurogenesis during chronic neurodegeneration
De Lucia C, Rinchon A, Olmos-Alonso A, Riecken K, Fehse B, Boche D, Perry V, Gomez-Nicola D
BRAIN BEHAV IMMUN. 2016;55:179-190.

Достижения в разработке инструментов для редактирования генома.
Fehse B
2016. АЛЬМАНАХ 2016. 1. Aufl. Moskau: .

Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells
Hossain J, Ystaas L, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J, Miletic H
J GENE MED. 2016;18(9):234-43.

Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
Labenski V, Suerth J, Barczak E, Heckl D, Levy C, Bernadin O, Charpentier E, Williams D, Fehse B, Verhoeyen E, Schambach A
BIOMATERIALS. 2016;97:97-109.

Генная терапия на основе трансплантации гемопоэтичеcких стволовых клеток с использованием сайт-специфического редактирования генома
Lepik K, Popova M, Shakirova A, Sergeev V, Potter A, Barkhatov I, Fehse B, Afanasyev B
Genes & Cells (гены & клетки) . 2016;XI(2):21-31.

Long-term in vivo single-cell tracking reveals the switch of migration patterns in adult-born juxtaglomerular cells of the mouse olfactory bulb
Liang Y, Li K, Riecken K, Maslyukov A, Gomez-Nicola D, Kovalchuk Y, Fehse B, Garaschuk O
CELL RES. 2016;26(7):805-21.

Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases
Mock U, Hauber I, Fehse B
NAT PROTOC. 2016;11(3):598-615.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB-Barcode Technology
Selich A, Daudert J, Hass R, Philipp F, von Kaisenberg C, Paul G, Cornils K, Fehse B, Rittinghausen S, Schambach A, Rothe M
STEM CELL TRANSL MED. 2016;5(5):591-601.

Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation
Stahl T, Rothe C, Böhme M, Kohl A, Kröger N, Fehse B
INT J MOL SCI. 2016;17(9):E1515.

2015

Übersicht - Gentherapeutische Konzepte in der Onkologie
Abramowski P, Fehse B
TUMORDIAGN THER. 2015;36(06):333-336.

Combined Application of RGB Marking and Mass Spectrometric Imaging Facilitates Detection of Tumor Heterogeneity
Abramowski P, Kraus O, Rohn S, Riecken K, Fehse B, Schlüter H
CANCER GENOM PROTEOM. 2015;12(4):179-187.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Gentherapie - zurück in die Zukunft?
Fehse B
BIOspektrum. 2015;15(4):448.

Genetische Manipulation: klinische Anwendung.
Fehse B, Cornils K
2015. Hämatopoetische Stammzellen. Herr W, Theobald M, Ehninger G, Einsele H, Meyer R (Hrsg.). 1. Aufl. Köln: Deutscher Ärzte-Verlag, 21-24.

Themenbereich somatische Gentherapie: Translationale und klinische Forschung
Fehse B, Domasch S
2015. Dritter Gentechnologiebericht: Analyse einer Hochtechnologie. Müller-Röber B, Budisa N, Diekämper J, Domasch S, Fehse B, Hampel J, Hucho F, Hümpel A, Köchy K, Marx-Stölting L, Reich J, Rheinberger H, Ropers H, Taupitz J, Walter J, Zenke M (Hrsg.). 1. Aufl. Baden Baden: Nomos, 211-308.

Multicolor RGB Marking Allows Morphometric and Functional Analysis of Hippocampal Granule Neurons at the Single-Cell Level
Gomez-Nicola D, Riecken K, Perry V, Fehse B
HUM GENE THER. 2015;26(6):332-333.

Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis
Heim D, Cornils K, Schulze K, Fehse B, Lohse A, Brümmendorf T, Wege H
ONCOGENE. 2015;34(3):385-393.

Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients
Kruchen A, Stahl T, Gieseke F, Binder T, Özcan Z, Meisel R, Kreyenberg H, Bader P, Gruhn B, Greil J, Pfeiffer M, Döring M, Handgretinger R, Fehse B, Müller I
BONE MARROW TRANSPL. 2015;50(10):1367-1370.

Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I
Kühn S, Koehne T, Cornils K, Markmann S, Riedel C, Pestka J, Schweizer M, Baldauf C, Yorgan T, Krause M, Keller J, Neven M, Breyer S, Stücker R, Muschol N, Busse B, Braulke T, Fehse B, Amling M, Schinke T
HUM MOL GENET. 2015;24(24):7075-7086.

Gezielter CCR5-Knockout in primären T-Lymphozyten zur Verhinderung der HIV-Infektion
Mock U, Fehse B
2015. Connexi. The Paideia Group, 14-16.

mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5
Mock U, Machowicz R, Hauber I, Horn S, Abramowski P, Berdien B, Hauber J, Fehse B
NUCLEIC ACIDS RES. 2015;43(11):5560-5571.

Targeting species D adenoviruses replication to counteract the epidemic keratoconjunctivitis
Nikitenko N, Speiseder T, Groitl P, Spirin P, Prokofjeva M, Lebedev T, Rubtsov P, Lam E, Riecken K, Fehse B, Dobner T, Prassolov V
BIOCHIMIE. 2015;113:10-16.

УНИВЕРСАЛЬНАЯ МОДУЛЬНАЯ СИСТЕМА СКРИНИНГА IN VITRO ПОТЕНЦИАЛЬНЫХ ИНГИБИТОРОВ РЕПЛИКАЦИИ ВИЧ-1
Prokof'eva M, Orlova N, Gornostaeva A, Shul'gin A, Nikitenko N, Senchenko V, Lebedev T, Spirin P, Riecken K, Fehse B, Stocking C, Prasolov V
MOL BIOL (MOSK). 2015;48(2):344-8.

Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
Stahl T, Böhme M, Kröger N, Fehse B
EXP HEMATOL. 2015;43(6):462-468.

Erratum for "Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors"
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-847.

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors
Trepel M, Körbelin J, Spies E, Heckmann M, Hunger A, Fehse B, Katus H, Kleinschmidt J, Müller O, Michelfelder S
GENE THER. 2015;22(10):840-7.

CD133 marks a stem cell population that drives human Primary Myelofibrosis
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N
HAEMATOLOGICA. 2015;100(6):768-79.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

2014

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
Berdien B, Mock U, Atanackovic D, Fehse B
GENE THER. 2014;21:539–548.

Multiplexing clonality: combining RGB marking and genetic barcoding
Cornils K, Thielecke L, Hüser S, Forgber M, Thomaschewski M, Kleist N, Hussein K, Riecken K, Volz T, Gerdes S, Glauche I, Dahl A, Dandri M, Roeder I, Fehse B
NUCLEIC ACIDS RES. 2014;42(7):e56.

Neural stem cell-based intraocular administration of ciliary neurotrophic factor attenuates the loss of axotomized ganglion cells in adult mice
Flachsbarth K, Kruszewski K, Jung G, Jankowiak W, Riecken K, Wagenfeld L, Richard G, Fehse B, Bartsch U
INVEST OPHTH VIS SCI. 2014;55(11):7029-7039.

In-vivo RGB marking and multicolour single-cell tracking in the adult brain
Gomez-Nicola D, Riecken K, Fehse B, Perry V
SCI REP-UK. 2014;4:7520.

Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration
Gomez-Nicola D, Suzzi S, Vargas-Caballero M, Fransen N, Al-Malki H, Cebrian-Silla A, Garcia-Verdugo J, Riecken K, Fehse B, Perry V
BRAIN. 2014;137(Pt 8):2312-28.

Selectins mediate small cell lung cancer systemic metastasis
Heidemann F, Schildt A, Schmid K, Bruns O, Riecken K, Jung C, Ittrich H, Wicklein D, Reimer R, Fehse B, Heeren J, Lüers G, Schumacher U, Heine M
PLOS ONE. 2014;9(4):e92327.

Low frequency of calreticulin mutations in MDS patients
Heuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol F
LEUKEMIA. 2014.

Gentherapie
Köchy K, Domasch S, Fehse B
2014. Handbuch Ethik & Recht der Forschung am Menschen. Lenk C, Duttge G, Fangerau H (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 427 - 432.

Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
Mock U, Riecken K, Berdien B, Qasim W, Chan E, Cathomen T, Fehse B
SCI REP-UK. 2014;4:6409.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism
Oehler N, Volz T, Bhadra O, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok J, Lohse A, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M
HEPATOLOGY. 2014.

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R, Chaturvedi A, Stadler M, Eder M, Göhring G, Koenigsmann M, Kloos A, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kreipe H, Ganser A, Kröger N, Heuser M
LEUKEMIA. 2014;28(7):1552-5.

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients
Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kröger N, Atanackovic D
BLOOD CANCER J. 2014;4:e212.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder T, Fehse B, Kröger N
MEDIAT INFLAMM. 2014;2014:418292.

Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
Triviai I, Ziegler M, Bergholz U, Oler A, Stübig T, Prassolov V, Fehse B, Kozak C, Kröger N, Stocking C
P NATL ACAD SCI USA. 2014;111(23):8595 - 8600.

2013

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy
Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B
HUM VACC IMMUNOTHER. 2013;9(6):1205-16.

Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral LTR vector
Cornils K, Bartholomae C, Thielecke L, Lange C, Arens A, Glauche I, Mock U, Riecken K, Gerdes S, von Kalle C, Schmidt M, Roeder I, Fehse B
EXP HEMATOL. 2013;41(1):28-38.e3.

Stem cell clonality -- theoretical concepts, experimental techniques, and clinical challenges
Glauche I, Bystrykh L, Eaves C, Roeder I
BLOOD CELL MOL DIS. 2013;50(4):232-40.

Genetically modified neural stem cells for a local and sustained delivery of neuroprotective factors to the dystrophic mouse retina
Jung G, Sun J, Petrowitz B, Riecken K, Kruszewski K, Jankowiak W, Kunst F, Skevas C, Richard G, Fehse B, Bartsch U
STEM CELL TRANSL MED. 2013;2(12):1001-10.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Fucoidans as potential inhibitors of HIV-1
Prokofjeva M, Imbs T, Shevchenko N, Spirin P, Horn S, Fehse B, Zvyagintseva T, Prassolov V
MAR DRUGS. 2013;11(8):3000-14.

A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses
Prokofjeva M, Riecken K, Spirin P, Yanvarév D, Düsedau A, Ellinger B, Fehse B, Stocking C, Prassolov V
AIDS RES THER. 2013;10(1):1.

Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene
Zhan H, Gilmour K, Chan L, Farzaneh F, McNicol A, Xu J, Adams S, Fehse B, Veys P, Thrasher A, Gaspar H, Qasim W
PLOS ONE. 2013;8(10):e77106.

2012

SOCS3 promotes interleukin-17 expression of human T cells.
Kleinsteuber K, Heesch K, Schattling S, Sander-Juelch C, Mock U, Riecken K, Fehse B, Fleischer B, Jacobsen M
BLOOD. 2012;120(22):4374-4382.

Efficient lentiviral transduction and transgene expression in primary human B cells.
Mock U, Thiele R, Uhde A, Fehse B, Horn S
HUM GENE THER METHOD. 2012;23(6):408-415.

Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.
Prokofjeva M, Spirin P, Yanvarev D, Ivanov A, Novikov M, Stepanov O, Gottikh M, Kochetkov S, Fehse B, Stocking C, Prassolov V
ACTA NATURAE. 2012;3(4):55-65.

RGB marking with lentiviral vectors for multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Benten D, Fehse B
NAT PHYS. 2012;7(5):839-849.

RGB marking : Vielfarbige Zellmarkierung zur klonalen Analyse
Riecken K, Thomaschewski M, Warlich M, Cornils K, Benten D, Fehse B
Laborwelt. 2012;13(1):7-9.

p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J, Riecken K, Baranowsky A, Streichert T, Lange T, Spiro A, Albers J, Seitz S, Zustin J, Amling M, Fehse B, Schinke T
CANCER LETT. 2012;317(1):106-113.

2011

Control of bone formation by the serpentine receptor Frizzled-9.
Albers J, Schulze J, Beil F, Gebauer M, Baranowsky A, Keller J, Marshall R, Wintges K, Friedrich F, Priemel M, Schilling A, Rueger J, Cornils K, Fehse B, Streichert T, Sauter G, Jakob F, Insogna K, Pober B, Knobeloch K, Francke U, Amling M, Schinke T
J CELL BIOL. 2011;192(6):1057-1072.

Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U, Haferlach T, Fehse B, Schnittger S, Kröger N
SCI WORLD J. 2011;11:310-319.

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U, Balabanov S, Bali D, Dierlamm J, Balabanov M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf T
EXP HEMATOL. 2011;39(1):62-66.

Gentherapie in Deutschland. Eine Einführung
Domasch S, Fehse B
2011. Gentherapie in Deutschland: Eine interdisziplinäre Bestandsaufnahme. Themenband des Gentechnologieberichts. Forum W - Wissenschaftlicher Verlag: 31-40.

Genetic Modifications – Possibilities and Limits of Gene Therapy
Fehse B
2011. Human Nature and Self Design. mentis Verlag Paderborn: 113-136.

Stand wissenschaftlicher und medizinischer Entwicklungen
Fehse B, Baum C, Schmidt M, Kalle C
2011. Gentherapie in Deutschland: Eine interdisziplinäre Bestandsaufnahme. Themenband des Gentechnologieberichts. Forum W - Wissenschaftlicher Verlag: 41-126.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Riecken K, Fehse B, Mack E, Stiewe T, Doerr H, Speidel D, Cinatl J, Riecken K
CELL DEATH DIS. 2011;2:e243.

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.
Newrzela S, Cornils K, Heinrich T, Schläger J, Yi J, Lysenko O, Kimpel J, Fehse B, Dorothee V
MOL MED. 2011;17(11-12):1223-1232.

Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.
Preuß E, Muik A, Riecken K, Otte J, von Laer D, Fehse B
J MOL MED. 2011;89(11):1113-1124.

RGB marking facilitates multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Warlich M, Volz T, Cornils K, Niebuhr B, Täger M, Lütgehetmann M, Pollok J, Stocking C, Dandri-Petersen M, Benten D, Fehse B
NAT MED. 2011;17(4):504-509.

Gene therapy strategies: can we eradicate HIV?
van Lunzen J, Fehse B, Hauber J
CURR HIV-AIDS REP. 2011;8(2):78-84.

2010

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2010;45(9):1404-1407.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Christian T, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander A, Kröger N
BLOOD. 2010;116(18):3572-3581.

Neue Wege der Stammzellforschung: Reprogrammierung von differenzierten Körperzellen
Beier H, Fehse B, Friedrich B, Götz M, Hansmann I, Hucho F, Köchy K, Müller-Röber B, Rheinberger H, Reich J, Robpers H, Schöler H, Schöne-Seifert B, Sperling K, Tanner K, Taupitz J, Wobus A
J Reprodmed Endokrinol. 2010;7:68-77.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.
Neth O, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuketang F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston R, Klein N, Zander A
BONE MARROW TRANSPL. 2010;45(1):13-9.

TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy.
Preuß E, Treschow A, Newrzela S, Brücher D, Riecken K, Felldin U, Alici E, Gahrton G, von Laer D, Dilber M, Fehse B
HUM GENE THER. 2010;21(8):929-941.

Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Rothweiler F, Michaelis M, Brauer P, Otte J, Riecken K, Fehse B, Doerr H, Wiese M, Kreuter J, Al-Abed Y, Nicoletti F, Cinatl J
NEOPLASIA. 2010;12(12):1023-1030.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010).
Stocking C, Grez M, Fehse B, von Laer D, Itoh K, Prassolov V, Nowock J, Kühlcke K, Just U, Schröder T, Klump H, Schiedlmeier B, Grassman E, Meyer J, Li Z, Schambach A, Modlich U, Kustikova O, Galla M, Jürgen B, Zander A, Baum C
HUM GENE THER. 2010;21(11):1501-1503.

Highly efficient lentiviral transduction of phenotypically and genotypically characterized endothelial progenitor cells from adult peripheral blood.
Stockschlaeder M, Shardakova O, Riecken K, Stoldt V, Fehse B, Giers G, Scharf R
BLOOD COAGUL FIBRIN. 2010;21(5):464-473.

Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation.
Vafaizadeh V, Klemmt P, Brendel C, Riecken K, Doebele C, Britt K, Grez M, Fehse B, Desriviéres S, Groner B
STEM CELLS. 2010;28(5):928-938.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

2009

Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Bacher U, Asenova S, Badbaran A, Zander A, Alchalby H, Fehse B, Kröger N, Lange C, Ayuketang Ayuk F
CLIN EXP MED. 2009.

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A, Kröger N
EXP HEMATOL. 2009;37(1):135-142.

Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance.
Cornils K, Lange C, Schambach A, Brugman M, Nowak R, Lioznov M, Baum C, Fehse B
MOL THER. 2009;17(1):131-143.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuketang Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A
BLOOD. 2009;113(8):1866-1868.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N, Badbaran A, Lioznov M, Schwartz S, Zeschke S, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A
EXP HEMATOL. 2009;37(7):791-798.

Retroviral insertion site analysis in dominant haematopoietic clones.
Kustikova O, Modlich U, Fehse B
Methods Mol Biol. 2009;506:373-390.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuketang Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander A, Blaise D, Mohty M, Kröger N
BONE MARROW TRANSPL. 2009.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Lippert E, Girodon F, Hammond E, Jelinek J, Reading N, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal J, Skoda R, Hermouet S
HAEMATOLOGICA. 2009;94(1):38-45.

Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr G, Jücker M
GENE THER. 2009;16(4):570-573.

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M, Rothweiler F, Klassert D, von Deimling A, Riecken K, Fehse B, Kammerer B, Doerr H, Cinatl J
CANCER RES. 2009;69(2):416-421.

Syngenic graft-versus-chronic-myeloid-leukemia-effect?
Ocheni S, Schafhausen P, Bacher U, Fehse B, Kröger N
CTT-Cell Ther Transpl. 2009;1(3):66-68.

Diva-Fit: A step-by-step manual for generating high-resolution graphs and histogram overlays of flow cytometry data obtained with FACSDiva software
Riecken K, Fehse B
CTT-Cell Ther Transpl. 2009;1(4):1-4.

Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis.
Riecken K, Mock U, Petrowitz B, Bartsch U, Fehse B
GENE THER. 2009.

2008

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander A, Fehse B, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2008;93(3):423-430.

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia.
Ayuketang Ayuk F, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander A, Kröger N
LEUKEMIA RES. 2008;32(8):1200-1206.

Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander A
EXP HEMATOL. 2008;36(8):1047-1054.

Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander A
BIOL BLOOD MARROW TR. 2008;14(8):913-919.

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bacher U, Zander A, Haferlach T, Schnittger S, Fehse B, Kröger N
BONE MARROW TRANSPL. 2008;42(3):145-157.

Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.
Bennour E, Ferrand C, Rémy-Martin J, Certoux J, Gorke S, Qasim W, Gaspar H, Baumert T, Duperrier A, Deschamps M, Fehse B, Tiberghien P, Robinet E
HUM GENE THER. 2008;19(7):699-709.

Clinical application of a retroviral gene transfer protocol based on centrifugation-mediated vector preloading.
Fehse B
HUM GENE THER. 2008;19(6):655-658.

Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B, Roeder I
GENE THER. 2008;15(2):143-153.

Overexpression of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase inhibits GM-CSF-dependent colony formation of CD34+ hematopoietic progenitor cells.
Hoxha E, Fehse B, Ortmeyer G, Stocking C, Mayr G, Jücker M
LEUKEMIA LYMPHOMA. 2008;49(6):1206-1208.

Retroviral integration site analysis in hematopoietic stem cells.
Kustikova O, Baum C, Fehse B
Methods Mol Biol. 2008;430:255-267.

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M, Badbaran A, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2008;41(10):913-916.

Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM.
Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander A
BONE MARROW TRANSPL. 2008;42(2):121-128.

Resistance of mature T cells to oncogene transformation.
Newrzela S, Cornils K, Li Z, Baum C, Brugman M, Hartmann M, Meyer J, Hartmann S, Hansmann M, Fehse B, von Laer D
BLOOD. 2008;112(6):2278-2286.

Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF.
Siebolts U, Thiele J, Zander T, Ditschkowski M, Beelen D, Kröger N, Fehse B, Wickenhauser C
ONCOL REP. 2008;19(1):287-292.

A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis
Weber K, Bartsch U, Stocking C, Fehse B
MOL THER. 2008;16(4):698-706.

2007

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, Reiter A, Zabelina T, Zander A, Fehse B
BLOOD. 2007;109(3):1316-1321.

Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.
Kustikova O, Geiger H, Li Z, Brugman M, Chambers S, Shaw C, Pike-Overzet K, de Ridder D, Staal F, von Keudell G, Cornils K, Nattamai K, Modlich U, Wagemaker G, Goodell M, Fehse B, Baum C
BLOOD. 2007;109(5):1897-1907.

CD34 modulates the trafficking behavior of hematopoietic cells in vivo.
Lange C, Li Z, Fang L, Baum C, Fehse B
STEM CELLS DEV. 2007;16(2):297-304.

Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene.
Li Z, Kustikova O, Kamino K, Neumann T, Rhein M, Grassman E, Fehse B, Baum C
ANN NY ACAD SCI. 2007;1106:95-113.

Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A, Horstmann M, Fehse B, Ortmeyer G, Niemeyer C, Stocking C, Mayr G, Jücker M
GENE THER. 2007;14(8):699-703.

Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA.
Meyer J, Rhein M, Schiedlmeier B, Kustikova O, Rudolph C, Kamino K, Neumann T, Yang M, Wahlers A, Fehse B, Reuther G, Schlegelberger B, Ganser A, Baum C, Li Z
LEUKEMIA. 2007;21(10):2171-2180.

2006

Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.
Baum C, Kustikova O, Modlich U, Li Z, Fehse B
HUM GENE THER. 2006;17(3):253-263.

Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation.
Fang L, Lange C, Engel M, Zander A, Fehse B
TRANSPLANTATION. 2006;82(10):1370-1373.

Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
Giordano F, Fehse B, Hotz-Wagenblatt A, Jonnakuty S, Del Val C, Appelt J, Nagy K, Kuehlcke K, Naundorf S, Zander A, Zeller W, Ho A, Fruehauf S, Laufs S
BONE MARROW TRANSPL. 2006;38(3):229-235.

Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuketang Ayuk F, Zander A, Fehse B
EXP HEMATOL. 2006;34(5):688-694.

CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
Oyekunle A, Koehl U, Schieder H, Ayuketang Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N
CYTOTHERAPY. 2006;8(4):375-380.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle A, Kröger N, Zabelina T, Ayuketang Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(1):45-50.

2005

Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells
Fang L, Fehse B, Engel M, Zander A, Kröger N
TRANSPLANTATION. 2005;79(3):369-371.

Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction
Krause K, Fehse B, Jaquet K, Lange C, Kyriazis K, Boczor S, Zander A, Kuck K
EXP CLIN CARDIOL. 2005;10(2):104-7.

Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking
Kustikova O, Fehse B, Modlich U, Yang M, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B, Li Z, Baum C
SCIENCE. 2005;308(5725):1171-4.

Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis
Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlcke K, Bunting K, Schmidt S, Deichmann A, von Kalle C, Fehse B, Baum C
BLOOD. 2005;105(11):4235-46.

Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function
Robinet E, Fehse B, Ebeling S, Sauce D, Ferrand C, Tiberghien P
CYTOTHERAPY. 2005;7(2):150-7.

2004

Chance or necessity?: Insertional mutagenesis in gene therapy and its consequences
Baum C, von Kalle C, Staal F, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams D
MOL THER. 2004;9(1):5-13.

Pois(s)on--it's a question of dose
Fehse B, Kustikova O, Bubenheim M, Baum C
GENE THER. 2004;11(11):879-81.

Tumor cells escape suicide gene therapy by genetic and epigenetic instability
Frank O, Rudolph C, Heberlein C, von Neuhoff N, Schröck E, Schambach A, Schlegelberger B, Fehse B, Ostertag W, Stocking C, Baum C
BLOOD. 2004;104(12):3543-9.

Self-inactivating retroviral vectors with improved RNA processing
Kraunus J, Schaumann D, Meyer J, Modlich U, Fehse B, Brandenburg G, von Laer D, Klump H, Schambach A, Bohne J, Baum C
GENE THER. 2004;11(21):1568-78.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander A
BLOOD. 2004;104(10):3361-3363.

Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene
Loew R, Selevsek N, Fehse B, von Laer D, Baum C, Fauser A, Kuehlcke K
MOL THER. 2004;9(5):738-46.

Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable
von Kalle C, Fehse B, Layh-Schmitt G, Schmidt M, Kelly P, Baum C
SEMIN HEMATOL. 2004;41(4):303-18.

2003

Side effects of retroviral gene transfer into hematopoietic stem cells
Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams D, von Kalle C
BLOOD. 2003;101(6):2099-114.

Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives
Baum C, Fehse B
Current opinion in molecular therapeutics. 2003;5(5):458-62.

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation.
Fehse N, Fehse B, Kröger N, Zabelina T, Freiberger P, Krüger W, Kabisch H, Erttmann R, Zander A
J HEMATOTH STEM CELL. 2003;12(2):237-242.

Hepatic lineages isolated from developing rat liver show different ways of maturation.
Fiegel H, Kluth J, Lioznov M, Holzhüter S, Fehse B, Zander A, Kluth D
BIOCHEM BIOPH RES CO. 2003;305(1):46-53.

Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population
Kustikova O, Wahlers A, Kuhlcke K, Stahle B, Zander A, Baum C, Fehse B
BLOOD. 2003;102(12):3934-7.

Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose
Li Z, Schwieger M, Lange C, Kraunus J, Sun H, van den Akker E, Modlich U, Serinsöz E, Will E, von Laer D, Stocking C, Fehse B, Schiedlmeier B, Baum C
EXP HEMATOL. 2003;31(12):1206-14.

2002

A novel 'sort-suicide' fusion gene vector for T cell manipulation
Fehse B, Kustikova O, Li Z, Wahlers A, Bohn W, Beyer W, Chalmers D, Tiberghien P, Kühlcke K, Zander A, Baum C
GENE THER. 2002;9(23):1633-1638.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
Kröger N, Schwerdtfeger R, Kiehl M, Sayer H, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, Zander A
BLOOD. 2002;100(3):755-760.

Murine leukemia induced by retroviral gene marking
Li Z, Düllmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kühlcke K, Eckert H, Fehse B, Baum C
SCIENCE. 2002;296(5567):497.

Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell
Li Z, Fehse B, Schiedlmeier B, Düllmann J, Frank O, Zander A, Ostertag W, Baum C
LEUKEMIA. 2002;16(9):1655-63.

Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant
Stute N, Fehse B, Schröder J, Arps S, Adamietz P, Held K, Zander A
J HEMATOTH STEM CELL. 2002;11(6):977-984.

Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR
Tögel F, Kröger N, Korioth F, Fehse B, Zander A
J HEMATOTH STEM CELL. 2002;11(6):971-976.

Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells
Wahlers A, Kustikova O, Zipfel P, Itoh K, Koester M, Heberlein C, Li Z, Schiedlmeier B, Skerka C, Fehse B, Baum C
MOL THER. 2002;6(3):313-320.

2001

Membrane-anchored peptide inhibits human immunodeficiency virus entry
Hildinger M, Dittmar M, Schult-Dietrich P, Fehse B, Schnierle B, Thaler S, Stiegler G, Welker R, von Laer D
J VIROL. 2001;75(6):3038-42.

The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro
Horn S, Meyer J, Heukeshoven J, Fehse B, Schulze C, Li S, Frey J, Poll S, Stocking C, Jücker M
LEUKEMIA. 2001;15(1):112-20.

2000

CD34 splice variant: an attractive marker for selection of gene-modified cells
Fehse B, Richters A, Putimtseva-Scharf K, Klump H, Li Z, Ostertag W, Zander A, Baum C
MOL THER. 2000;1(5 Pt 1):448-456.

1999

Rapid and efficient cloning of proviral flanking fragments by kanamycin resistance gene complementation
Fehse B, Kühlcke K, Langer A, Ostertag W, Lother H
NUCLEIC ACIDS RES. 1999;27(2):706-7.

1998

Impact of a new generation of gene transfer markers on gene therapy
Fehse B, Li Z, Schade U, Uhde A, Zander A
GENE THER. 1998;5(4):429-430.

Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin
Fehse B, Schade U, Li Z, Uhde A, Koch S, Goller B, Rüger R, Fehse N, Stockschläder M, Zander A
BRIT J HAEMATOL. 1998;102(2):566-74.

Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors
Hildinger M, Fehse B, Hegewisch-Becker S, John J, Rafferty J, Ostertag W, Baum C
HUM GENE THER. 1998;9(1):33-42.

Purging and haemopoietic progenitor cell selection by CD34+ cell separation
Krüger W, Gruber M, Hennings S, Fehse N, Fehse B, Gutensohn K, Kröger N, Zander A
BONE MARROW TRANSPL. 1998;21(7):665-671.

High-efficiency retroviral vector-mediated gene transfer into human T lymphocytes
Li Z, Schade U, Fehse B, Stockschläder M, Uhde A, Koch S, Goller B, Rüger R, Fehse N, Zander A
ADV EXP MED BIOL. 1998;451:375-378.

1997

Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene
Fehse B, Uhde A, Fehse N, Eckert H, Clausen J, Rüger R, Koch S, Ostertag W, Zander A, Stockschläder M
HUM GENE THER. 1997;8(15):1815-1824.

1995

Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination
Bergemann J, Kühlcke K, Fehse B, Ratz I, Ostertag W, Lother H
NUCLEIC ACIDS RES. 1995;23(21):4451-6.

Letzte Aktualisierung aus dem FIS: 27.11.2024 - 23:34 Uhr